Guggenheim analyst Eddie Hickman initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research initiated with an Outperform at RBC Capital
- GH Research PLC Reports 2024 Financial Results and Clinical Progress
- GH Research’s Promising Growth Potential: Buy Rating Backed by Strong Clinical Data and Financial Position
- Optimistic Buy Rating for GH Research Driven by Promising Clinical Data and Strong Financial Outlook
- Promising Trial Results and Strong Financials Justify Buy Rating for GH Research
Questions or Comments about the article? Write to editor@tipranks.com